title: Treatment of de novo acute myeloid leukaemia in Hong Kong: a twenty-year experience (1975 to 1996).
abstract: BACKGROUND
  Small patient numbers and short follow-up are common in some acute myeloid leukaemia (AML) studies and data on secondary malignancies after treatment of AML are rare.
  
  
  OBJECTIVE
  To determine the prognostic factors and long-term treatment results.
  
  
  METHODS
  A retrospective study of patients with de novo AML under the age of 60 over a 20-year period in which two induction therapy regimens: 7:3 (1975-1983) and 7:3:7 (1984-1996) and three consolidation chemotherapy regimens: 5:2 (1975-1983), 5:2:5 (1984-1990) and Ara-C/mitoxantrone (1991-1996) were used. Disease-free (DFS), overall survivals (OS) and prognostic factors were analysed.
  
  
  RESULTS
  Two-hundred and two of 276 (73%) patients attained complete remission (CR). The CR rates of 7:3 and 7:3:7 regimens were 70.5% and 74.5% respectively (p=0.92). The median DFS was 12 months and the projected DFS at 10- and 20-years were 23% and 21% respectively. For patients consolidated with 5:2, 5:2:5 and Ara-C/mitoxantrone, the median DFS was 15 m, 12 m and 11 m respectively and the projected ten-year DFS were 27%, 21% and 18% respectively (p=0.2). Ninety per cent of relapses occurred within two years from remission but there were two late relapses at 109 m and 120 m respectively. Young age and FAB M3 subtype were favourable prognostic factors to OS (p=0.04) and DFS (p=0.006) respectively. There was no secondary solid tumour in the long-term survivors.
  
  
  CONCLUSIONS
  Our experience confirmed the efficacy of standard-dose Ara-C/daunorubicin and the prognostic value of age and FAB subtype. Median and projected DFS were similar to western studies.
authors.affiliation: University Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong. jcschim@hkucc.hku.hk
authors.forename: C S
authors.initials: CS
authors.lastname: Chim
authors.forename: R
authors.initials: R
authors.lastname: Liang
authors.forename: Y L
authors.initials: YL
authors.lastname: Kwong
authors.forename: A K
authors.initials: AK
authors.lastname: Lie
authors.forename: D
authors.initials: D
authors.lastname: Todd
authors.forename: T K
authors.initials: TK
authors.lastname: Chan
mesh_terms: D000208:Acute Disease; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005260:Female; D006723:Hong Kong / Q000453:epidemiology; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies